HUTCHMED (China) Limited
HCM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HCM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HCM
HUTCHMED (China) Limited is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel oncology and immunology therapies, with three internally developed drugs marketed in China and a pipeline of over 20 clinical and late preclinical candidates [sec · filed 2026-03-05].
Key risk: Need for additional funding
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 12 clinical trials · 2 catalysts for HUTCHMED (China) Limited.
HUTCHMED (China) Limited is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel oncology and immunology therapies, with three internally developed drugs marketed in China and a pipeline of over 20 clinical and late preclinical candidates [sec · filed 2026-03-05].
- As of 2025-12-31, HUTCHMED reported cash & equivalents of $71.3M, total revenue of $548.5M, net income of $456.9M, shareholders' equity of $759.9M, and total debt of $118.1M [sec].
- The company has built an in-house oncology drug sales team of approximately 780 persons as of end of 2025 to support commercialization of fruquintinib, surufatinib, tazemetostat, and other drugs in China [sec · filed 2026-03-05].
- HUTCHMED's drug discovery engine has produced a pipeline of over 20 differentiated clinical and late pre-clinical stage drug candidates, with three now marketed [sec · filed 2026-03-05].
- The company's new drug product facility in Shanghai passed FDA Pre-Approval Inspection with zero observations in January 2026 and is expected to increase manufacturing capacity by over five times [sec · filed 2026-03-05].
- HUTCHMED partners globally with AstraZeneca for savolitinib and with Takeda for fruquintinib outside China, while retaining global rights to the rest of its portfolio [sec · filed 2026-03-05].
What works
- HUTCHMED has a profitable drug marketing and distribution platform in China through its Other Ventures operations, which it leverages to commercialize its own oncology innovations [sec · filed 2026-03-05].
- The company's drug discovery engine is considered a key competitive advantage, creating differentiated novel oncology and immunology treatments with global potential [sec · filed 2026-03-05].
- The Shanghai manufacturing facility passed FDA Pre-Approval Inspection with zero observations, supporting global supply and cost savings [sec · filed 2026-03-05].
- HUTCHMED has established global partnerships with AstraZeneca and Takeda for late-stage development and commercialization outside China [sec · filed 2026-03-05].
What to weigh
- HUTCHMED's Oncology/Immunology operations historically operated at a net loss, and future profitability depends on successful commercialization of its drug candidates [sec · filed 2026-03-05].
- The company used net cash of $64.7 million in operating activities in 2025, and there is no guarantee of generating positive cash flows from operations in the future [sec · filed 2026-03-05].
- HUTCHMED faces risks related to its need for additional funding and existing indebtedness [sec · filed 2026-03-05].
- The company is dependent on third-party therapies for combination trials, and any efficacy, manufacturing, or supply issues with those partners could harm its business [sec · filed 2026-03-05].
From the filings
Quoted directly from source documents.
HUTCHMED has built a large-scale and profitable drug marketing and distribution platform in China.
“We have built large-scale and profitable drug marketing and distribution capabilities through our Other Ventures operations, which primarily manufacture, market and distribute prescription drugs in China.”
SEC filings · March 5, 2026
The company's drug discovery engine is a key competitive advantage.
“We believe our world-class drug discovery engine is our key competitive advantage.”
SEC filings · March 5, 2026
HUTCHMED's pipeline includes over 20 differentiated clinical and late pre-clinical drug candidates.
“has already produced a pipeline of over 20 differentiated clinical and late pre-clinical stage drug candidates covering both novel and validated targets of which three are now marketed.”
SEC filings · March 5, 2026
The Shanghai facility passed FDA Pre-Approval Inspection with zero observations.
“The Shanghai facility passed Pre-Approval Inspection of FDA with zero observations in January 2026.”
SEC filings · March 5, 2026
Catalyst timeline
- 2028-05-30 · Phase3_Topline — Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safet — Topline data from a Phase 3 study will provide efficacy and safety results for a key pipeline candidate.
- 2028-12-30 · Phase3_Topline · r-gemox — Phase 3 Topline: A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, an — Topline data from a Phase 3 study comparing a regimen including r-gemox will inform regulatory and commercial potential.
Risks & what to watch (4)›
Key risks
- Need for additional funding — HUTCHMED may require additional capital to support its operations and development activities [sec · filed 2026-03-05].
- Oncology/Immunology net losses — The Oncology/Immunology operations have historically operated at a net loss, and profitability depends on successful commercialization [sec · filed 2026-03-05].
- Dependence on third-party combinations — Combination therapy development relies on third-party drugs; issues with partners could cause delays or shortages [sec · filed 2026-03-05].
- Accounts receivable collection risk — Amounts due to HUTCHMED are not covered by collateral or credit insurance, posing collection risk [sec · filed 2026-03-05].
What to watch
- Phase 3 topline results for a multicenter, randomized, double-blind study expected on 2028-05-30 [upcoming catalysts].
- Phase 3 topline results for a study evaluating efficacy and safety of r-gemox expected on 2028-12-30 [upcoming catalysts].
- Commercialization progress of fruquintinib, surufatinib, and tazemetostat in China and globally [sec · filed 2026-03-05].
- Regulatory and manufacturing milestones at the new Shanghai facility [sec · filed 2026-03-05].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run HUTCHMED (China) Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HUTCHMED (China) Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
63.2 months
D/E 0.41 · 2% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~639d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
50
Total value held
$46.4M
| Holder | Shares | Value |
|---|---|---|
| schroder investment management group | 1,477,494 | $22.1M |
| state street corp | 304,829 | $4.6M |
| aia group ltd | 291,229 | $4.4M |
| m&g plc | 255,468 | $3.8M |
| renaissance technologies llc | 132,062 | $2.0M |
| bnp paribas financial markets | 106,504 | $1.6M |
| jane street group, llc | 76,514 | $1.1M |
| tidal investments llc | 67,385 | $1.0M |
| dimensional fund advisors lp | 55,969 | $837K |
| xy capital ltd | 48,394 | $724K |
Showing top 10 of 50 institutional holders of HUTCHMED (China) Limited. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 0.3%
- Days to cover
- 8.9
- Shares short
- 306,832
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HCM short interestGovernance
Frequently asked questions
What is the AI investment thesis for HUTCHMED (China) Limited?
HUTCHMED (China) Limited is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel oncology and immunology therapies, with three internally developed drugs marketed in China and a pipeline of over 20 clinical and late preclinical candidates [sec · filed 2026-03-05].
What is HUTCHMED (China) Limited's next catalyst?
HUTCHMED (China) Limited's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safet" — expected May 30, 2028.
Who is the CEO of HUTCHMED (China) Limited?
Mr. Chig Fung Cheng BEc, CA is the chief executive officer of HUTCHMED (China) Limited (HCM).
Where is HUTCHMED (China) Limited headquartered?
HUTCHMED (China) Limited (HCM) is headquartered in Hong Kong, Hong Kong.
What therapeutic areas does HUTCHMED (China) Limited focus on?
HUTCHMED (China) Limited develops therapies across Oncology, Immunology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.